Connor, Clark & Lunn Investment Management Ltd. Crinetics Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $28.9 Billion
- Q3 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 12,544 shares of CRNX stock, worth $535,252. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,544Holding current value
$535,252% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding CRNX
# of Institutions
248Shares Held
93.6MCall Options Held
695KPut Options Held
80.6K-
Vanguard Group Inc Valley Forge, PA9.17MShares$391 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.38MShares$358 Million0.06% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.48MShares$277 Million2.29% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$266 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA5.77MShares$246 Million1.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.29B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...